Page 1607 - Hematology_ Basic Principles and Practice ( PDFDrive )

1431.e2 Part VII Hematologic Malignancies

46. Loiarro M, Gallo G, Fanto N, et al: Identification of critical residues of 71. Dellagi K, Dupouey P, Brouet JC, et al: Waldenström’s macroglobulin-
the MYD88 death domain involved in the recruitment of downstream emia and peripheral neuropathy: a clinical and immunologic study of
kinases. J Biol Chem 284:28093, 2009. 25 patients. Blood 62:280, 1983.
47. Lin SC, Lo YC, Wu H: Helical assembly in the MYD88-IRAK4-IRAK2 72. Nobile-Orazio E, Marmiroli P, Baldini L, et al: Peripheral neuropathy
complex in TLR/IL-1R signaling. Nature 465:885, 2010. in macroglobulinemia: Incidence and antigen-specificity of M proteins.
48. Kawagoe T, Sato S, Matsushita K, et al: Sequential control of Toll-like Neurology 37:1506, 1987.
receptor dependent responses by IRAK1 and IRAK2. Nat Immunol 73. Treon SP, Hanzis C, Ioakimidis L, et al: Clinical characteristics
9:684, 2008. and treatment outcome of disease-related peripheral neuropathy in
49. Leleu X, Eeckhoute J, Jia X, et al: Targeting NF-κB in Waldenström Waldenström’s macroglobulinemia (WM) [abstract 8114]. J Clin Oncol
macroglobulinemia. Blood 111:5068, 2008. 28(Suppl):15s, 2010.
50. Treon SP, Cao Y, Xu L, et al: Somatic mutations in MYD88 and 74. Nemni R, Gerosa E, Piccolo G, et al: Neuropathies associated with
CXCR4 are determinants of clinical presentation and overall survival monoclonal gammopathies. Haematologica 79:557, 1994.
in Waldenström macroglobulinemia. Blood 123:2791, 2014. 75. Ropper AH, Gorson KC: Neuropathies associated with paraprotein-
51. Roccaro A, Sacco A, Jiminez C, et al: C1013G/CXCR4 acts as a driver emia. N Engl J Med 338:1601, 1998.
mutation of tumor progression and modulator of drug resistance in 76. Vital A: Paraproteinemic neuropathies. Brain Pathol 11:399, 2001.
lymphoplasmacytic lymphoma. Blood 123:4120, 2014. 77. Latov N, Braun PE, Gross RB, et al: Plasma cell dyscrasia and peripheral
52. Poulain S, Roumier C, Doye E, et al: Genomic landscape of CXCR4 neuropathy: identification of the myelin antigens that react with human
mutations in Waldenström’s macroglobulinemia [abstract 1610]. Blood paraproteins. Proc Natl Acad Sci USA 78:7139, 1981.
124:1627, 2014. 78. Chassande B, Leger JM, Younes-Chennoufi AB, et al: Peripheral neu-
53. Busillo JM, Amando S, Sengupta R, et al: Site-specific phosphorylation ropathy associated with IgM monoclonal gammopathy: correlations
of CXCR4 is dynamically regulated by multiple kinases and results in between M-protein antibody activity and clinical/electrophysiological
differential modulation of CXCR4 signaling. J Biol Chem 285:7805, features in 40 cases. Muscle Nerve 21:55, 1998.
2010. 79. Weiss MD, Dalakas MC, Lauter CJ, et al: Variability in the binding of
54. Dotta L, Tassone L, Badolato R: Clinical and genetic features of warts, anti-MAG and anti-SGPG antibodies to target antigens in demyelinating
hypogammaglobulinemia, infections and myelokathexis (WHIM) neuropathy and IgM paraproteinemia. J Neuroimmunol 95:174, 1999.
syndrome. Curr Mol Med 11:317, 2011. 80. Latov N, Hays AP, Sherman WH: Peripheral neuropathy and anti-
55. Cao Y, Hunter ZR, Liu X, et al: The WHIM-like CXCR4 S338X somatic MAG antibodies. Crit Rev Neurobiol 3:301, 1988.
mutation activates AKT and ERK, and promotes resistance to ibrutinib 81. Dalakas MC, Quarles RH: Autoimmune ataxic neuropathies (sensory
and other agents used in the treatment of Waldenström’s macroglobu- ganglionopathies): are glycolipids the responsible autoantigens? Ann
linemia. Leukemia 29:169, 2015. Neurol 39:419, 1996.
56. Cao Y, Hunter ZR, Liu X, et al: CXCR4 WHIM-like frameshift and 82. Eurelings M, Ang CW, Notermans NC, et al: Antiganglioside anti-
nonsense mutations promote ibrutinib resistance but do not supplant bodies in polyneuropathy associated with monoclonal gammopathy.
MYD88 L265P directed signaling in Waldenström macroglobulinaemia Neurology 57:1909, 2001.
cells. Br J Haematol 168:701, 2015. 83. Ilyas AA, Quarles RH, Dalakas MC, et al: Monoclonal IgM in a patient
57. Tournilhac O, Santos DD, Xu L, et al: Mast cells in Waldenström’s with paraproteinemic polyneuropathy binds to gangliosides containing
macroglobulinemia support lymphoplasmacytic cell growth through disialosyl groups. Ann Neurol 18:655, 1985.
CD154/CD40 signaling. Ann Oncol 17:1275, 2006. 84. Willison HJ, O’Leary CP, Veitch J, et al: The clinical and laboratory
58. Zhou Y, Liu X, Xu L, et al: Matrix metalloproteinase-8 is overexpressed features of chronic sensory ataxic neuropathy with anti-disialosyl IgM
in Waldenström’s macroglobulinemia cells, and specific inhibition of antibodies. Brain 124:1968, 2001.
this metalloproteinase blocks release of soluble CD27. Clin Lymphoma 85. Lopate G, Choksi R, Pestronk A: Severe sensory ataxia and demy-
Myeloma Leuk 11:172, 2011. elinating polyneuropathy with IgM anti-GM 2 and GalNAc-GD1A
59. Ngo HT, Leleu X, Lee J, et al: SDF-1/CXCR4 and VLA-4 interaction antibodies. Muscle Nerve 25:828, 2002.
regulates homing in Waldenström macroglobulinemia. Blood 112:150, 86. Jacobs BC, O’Hanlon GM, Breedland EG, et al: Human IgM para-
2008. proteins demonstrate shared reactivity between Campylobacter jejuni
60. Ho AW, Hatjiharissi E, Ciccarelli BT, et al: CD27-CD70 interactions in lipopolysaccharides and human peripheral nerve disialylated ganglio-
the pathogenesis of Waldenström macroglobulinemia. Blood 112:4683, sides. J Neuroimmunol 80:23, 1997.
2008. 87. Nobile-Orazio E, Manfredini E, Carpo M, et al: Frequency and clinical
61. Merlini G, Farhangi M, Osserman EF: Monoclonal immunoglobulins correlates of antineural IgM antibodies in neuropathy associated with
with antibody activity in myeloma, macroglobulinemia and related IgM monoclonal gammopathy. Ann Neurol 36:416, 1994.
plasma cell dyscrasias. Semin Oncol 13:350, 1986. 88. Gordon PH, Rowland LP, Younger DS, et al: Lymphoproliferative
62. Farhangi M, Merlini G: The clinical implications of monoclonal disorders and motor neuron disease: an update. Neurology 48:1671,
immunoglobulins. Semin Oncol 13:366, 1986. 1997.
63. Marmont AM, Merlini G: Monoclonal autoimmunity in hematology. 89. Pavord SR, Murphy PT, Mitchell VE: POEMS syndrome and Walden-
Haematologica 76:449, 1991. ström’s macroglobulinaemia. J Clin Pathol 49:181, 1996.
64. Mackenzie MR, Babcock J: Studies of the hyperviscosity syndrome. II: 90. Crisp D, Pruzanski W: B-cell neoplasms with homogeneous cold-
Macroglobulinemia. J Lab Clin Med 85:227, 1975. reacting antibodies (cold agglutinins). Am J Med 72:915, 1982.
65. Gertz MA, Kyle RA: Hyperviscosity syndrome. J Intensive Care Med 91. Pruzanski W, Shumak KH: Biologic activity of cold-reacting autoanti-
10:128, 1995. bodies (first of two parts). N Engl J Med 297:538, 1977.
66. Kwaan HC, Bongu A: The hyperviscosity syndromes. Semin Thromb 92. Pruzanski W, Shumak KH: Biologic activity of cold-reacting autoanti-
Hemost 25:199, 1999. bodies (second of two parts). N Engl J Med 297:583, 1977.
67. Singh A, Eckardt KU, Zimmermann A, et al: Increased plasma viscosity 93. Whittaker SJ, Bhogal BS, Black MM: Acquired immunobullous disease:
as a reason for inappropriate erythropoietin formation. J Clin Invest a cutaneous manifestation of IgM macroglobulinaemia. Br J Dermatol
91:251, 1993. 135:283, 1996.
68. Menke MN, Feke GT, McMeel JW, et al: Hyperviscosity-related 94. Daoud MS, Lust JA, Kyle RA, et al: Monoclonal gammopathies and
retinopathy in Waldenström’s macroglobulinemia. Arch Ophthalmol associated skin disorders. J Am Acad Dermatol 40:507, 1999.
124:1601, 2006. 95. Gad A, Willen R, Carlen B, et al: Duodenal involvement in Walden-
69. Merlini G, Baldini L, Broglia C, et al: Prognostic factors in symptom- ström’s macroglobulinemia. J Clin Gastroenterol 20:174, 1995.
atic Waldenström’s macroglobulinemia. Semin Oncol 30:211, 2003. 96. Amrein PC, Compton CC: Case 3-1990—a 66-year-old woman with
70. Stone MJ: Waldenström’s macroglobulinemia: hyperviscosity syndrome Waldenström’s macroglobulinemia, diarrhea, anemia, and persistent
and cryoglobulinemia. Clin Lymphoma Myeloma 9:97, 2009. gastrointestinal bleeding. N Engl J Med 322:183, 1990.